NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Quantumzyme's Enzyme Engineering Innovations at CCE-2026 Conference
TL;DR
Quantumzyme's enzyme engineering platform offers pharmaceutical manufacturers competitive advantages through cost-efficient production and sustainable API manufacturing pathways.
Quantumzyme uses computational enzyme engineering and biocatalytic routes to reduce waste, lower carbon intensity, and improve process reliability in pharmaceutical manufacturing.
Quantumzyme's sustainable enzyme technology supports cleaner pharmaceutical production, reducing environmental impact and advancing global sustainability goals for future generations.
Quantumzyme is showcasing innovative enzyme engineering for green ibuprofen synthesis and chiral molecule production at the CCE-2026 conference in Boston.
Found this article helpful?
Share it with your network and spread the knowledge!
Quantumzyme is announcing its participation in the Catalysis and Chemical Engineering Conference (CCE-2026) where it will showcase its enzyme engineering platform for sustainable pharmaceutical manufacturing, including green ibuprofen synthesis and expanded API production applications.
The CCE-2026 conference is scheduled for March 9-11, 2026, in Boston, MA.
Quantumzyme will present advancements in green ibuprofen synthesis using biocatalytic routes, expansion of its enzyme engineering platform to high-volume Active Pharmaceutical Ingredients (APIs), and new applications in chiral molecule synthesis supported by next-generation ketoreductase (KRED) enzymes.
The technology addresses global sustainability goals by reducing waste, solvent consumption, and carbon intensity in API production while improving process reliability and supporting U.S. onshoring and supply-chain resilience for essential medicines.
Quantumzyme plans to engage with researchers, academic collaborators, pharmaceutical manufacturers, process development teams, technology developers, innovation partners, and investors focused on green chemistry and biomanufacturing.
The platform enables greener, more reliable, and locally scalable biocatalytic pathways that reduce environmental impact, lower manufacturing costs, and provide more efficient alternatives to traditional chemical synthesis methods.
The approach reduces waste and solvent consumption, lowers carbon intensity in API production, and supports cleaner pharmaceutical manufacturing compared to legacy chemistries that generate significant waste.
For more information and updates, visit www.quantumzymecorp.com and the Company's profile at www.otcmarkets.com/stock/QTZM.
Quantumzyme aims to revolutionize chemical processes through sustainable, enzyme-based solutions that support the transformation of pharmaceutical manufacturing toward environmentally responsible production and strengthen domestic API manufacturing capacity.
Curated from NewMediaWire
